Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05254912 · ClinicalTrials.gov registry record · Phase 2
Photoallergic Potential of 6% Bemotrizinol
A Phase 2 study, sponsored by dsm-firmenich Switzerland.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT05254912 is a Phase 2 study that has completed, run by dsm-firmenich Switzerland. The registered enrollment target is 50 participants.
The verdict
NCT05254912, a Phase 2 study, has completed, sponsored by dsm-firmenich Switzerland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This clinical trial will assess the photoallergic potential of BEMT (6%), compared to a vehicle control and a negative control.
Interventions
- OTHER Vehicle
- DRUG 6% Bemotrizinol in sunscreen formulation
- DRUG 6% Bemotrizinol in petrolatum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2022-04-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05254912
The ClinicalTrials.gov registry entry for NCT05254912 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is dsm-firmenich Switzerland, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle is the first listed.
NCT05254912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05254912 about?
NCT05254912 is a clinical study titled "Photoallergic Potential of 6% Bemotrizinol". This clinical trial will assess the photoallergic potential of BEMT (6%), compared to a vehicle control and a negative control.
What is the current status of trial NCT05254912?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-03-07. Estimated completion is 2022-04-22.
What interventions are being tested in trial NCT05254912?
The interventions under investigation include: Vehicle (OTHER), 6% Bemotrizinol in sunscreen formulation (DRUG), 6% Bemotrizinol in petrolatum (DRUG).
Who is sponsoring clinical trial NCT05254912?
This trial is sponsored by dsm-firmenich Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.